Zacks Research Has Bullish Outlook for IRWD FY2026 Earnings

Key Points

• Zacks Research raised Ironwood Pharmaceuticals’ FY2026 earnings forecast to $1.10 per share from $1.04, matching the current consensus estimate, while maintaining a “Hold” rating.
• Ironwood’s shares opened at $4.13, with a $682.4 million market capitalization and a one-year trading range of $1.01 to $5.78. Its latest quarterly results slightly missed expectations, with EPS of $0.31 versus $0.32 expected and revenue of $113.04 million versus $114.84 million estimated.
• Institutional ownership increased as several investment firms built or initiated positions, although company insiders recently sold shares; insiders own 9.3% of the stock. Analysts collectively rate IRWD “Moderate Buy,” with an average price target of $6.23.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Investment analysts at Zacks Research increased their FY2026 earnings estimates for shares of Ironwood Pharmaceuticals in a research report issued on Thursday, August 27th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings of $1.10 per share for the year, up from their prior forecast of $1.04. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $1.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals' Q1 2028 earnings at $0.02 EPS and Q2 2028 earnings at $0.01 EPS.

IRWD has been the topic of several other reports. Wall Street Zen upgraded Ironwood Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 22nd. Weiss Ratings upgraded Ironwood Pharmaceuticals from a "hold (c-)" rating to a "hold (c+)" rating in a research note on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Ironwood Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $6.23.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD opened at $4.13 on Monday. The company has a market capitalization of $682.44 million, a P/E ratio of 5.36 and a beta of 0.20. Ironwood Pharmaceuticals has a one year low of $1.01 and a one year high of $5.78. The stock has a 50-day moving average price of $4.14 and a 200 day moving average price of $3.89.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.01). Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%. The business had revenue of $113.04 million for the quarter, compared to analyst estimates of $114.84 million.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its stake in Ironwood Pharmaceuticals by 529.3% during the first quarter. Dimensional Fund Advisors LP now owns 2,082,055 shares of the biotechnology company's stock worth $7,307,000 after purchasing an additional 1,751,219 shares during the last quarter. Inspire Investing LLC bought a new stake in Ironwood Pharmaceuticals during the first quarter valued at $1,790,000. Pacer Advisors Inc. bought a new stake in Ironwood Pharmaceuticals during the first quarter valued at $3,982,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth $3,897,000. Finally, Globeflex Capital L P acquired a new stake in shares of Ironwood Pharmaceuticals during the second quarter worth $1,094,000.

Insider Activity

In related news, insider Ronald Silver sold 127,890 shares of the business's stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $4.52, for a total value of $578,062.80. Following the completion of the sale, the insider directly owned 313,680 shares of the company's stock, valued at $1,417,833.60. The trade was a 28.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Julie Mchugh sold 21,571 shares of the business's stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total value of $80,459.83. Following the completion of the sale, the director directly owned 250,749 shares of the company's stock, valued at approximately $935,293.77. This represents a 7.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 9.30% of the company's stock.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company's flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.